Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Cell Mol Med ; 17(5): 636-47, 2013 May.
Artigo em Inglês | MEDLINE | ID: mdl-23577651

RESUMO

The use of the mammal target of rapamycin (mTOR) inhibitors has been consolidated as the therapy of election for preventing graft rejection in kidney transplant patients, despite their immunosuppressive activity is less strong than anti-calcineurin agents like tacrolimus and cyclosporine A. Furthermore, as mTOR is widely expressed, rapamycin (a macrolide antibiotic produced by Streptomyces hygroscopicus) is recommended in patients presenting neoplasia due to its antiproliferative actions. Hence, we have investigated whether rapamycin presents side effects in the physiology of other cell types different from leucocytes, such as platelets. Blood samples were drawn from healthy volunteers and kidney transplant patients long-term medicated with rapamycin: sirolimus and everolimus. Platelets were either loaded with fura-2 or directly stimulated, and immunoassayed or fixed with Laemmli's buffer to perform the subsequent analysis of platelet physiology. Our results indicate that rapamycin evokes a biphasic time-dependent alteration in calcium homeostasis and function in platelets from kidney transplant patients under rapamycin regime, as demonstrated by the reduction in granule secretion observed and subsequent impairment of platelet aggregation in these patients compared with healthy volunteers. Platelet count was also reduced in these patients, thus 41% of patients presented thrombocytopenia. All together our results show that long-term administration of rapamycin to kidney transplant patients evokes alteration in platelet function.


Assuntos
Plaquetas/patologia , Cálcio/metabolismo , Homeostase/efeitos dos fármacos , Transplante de Rim , Inibidores de Proteínas Quinases/administração & dosagem , Inibidores de Proteínas Quinases/farmacologia , Serina-Treonina Quinases TOR/antagonistas & inibidores , Adulto , Idoso , Plaquetas/efeitos dos fármacos , Demografia , Ativação Enzimática/efeitos dos fármacos , Everolimo , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fosforilação/efeitos dos fármacos , Agregação Plaquetária/efeitos dos fármacos , Transdução de Sinais/efeitos dos fármacos , Sirolimo/administração & dosagem , Sirolimo/análogos & derivados , Sirolimo/farmacologia , Serina-Treonina Quinases TOR/metabolismo , Fatores de Tempo
2.
Cancers (Basel) ; 12(2)2020 Jan 21.
Artigo em Inglês | MEDLINE | ID: mdl-31973006

RESUMO

(1) Background: The structure of the Sigma 2 receptor/TMEM97 (σ2RTMEM97) has recently been reported. (2, 3) Methods and results: We used genetic and biochemical approaches to identify the molecular mechanism downstream of σ2R/TMEM97. The novel σ2R/TMEM97 fluorescent ligand, NO1, reduced the proliferation and survival of the triple negative breast cancer cell lines (TNBC: MDA-MB-231 and MDA-MB-468 cell lines), due to NO1-induced apoptosis. Greater bioaccumulation and faster uptake of NO1 in MDA-MB-231 cells compared to MCF10A or MCF7 cell lines were also shown. Accordingly, elevated σ2R/TMEM97 expression was confirmed by Western blotting. In contrast to NO1, other σ2R/TMEM97 ligands, such as SM21 and PB28, enhanced MDA-MB-231 cell proliferation and migration. Store-operated calcium entry (SOCE) is crucial for different cancer hallmarks. Here, we show that NO1, but not other σ2R/TMEM97 ligands, reduced SOCE in MDA-MB-231 cells. Similarly, TMEM97 silencing in MDA-MB-231 cells also impaired SOCE. NO1 administration downregulated STIM1-Orai1 interaction, probably by impairing the positive regulatory effect of σ2R/TMEM97 on STIM1, as we were unable to detect interaction with Orai1. (4) Conclusion: σ2R/TMEM97 is a key protein for the survival of triple negative breast cancer cells by promoting SOCE; therefore, NO1 may become a good pharmacological tool to avoid their proliferation.

3.
Toxicology ; 244(2-3): 280-91, 2008 Feb 28.
Artigo em Inglês | MEDLINE | ID: mdl-18237838

RESUMO

We have investigated the effect of the seleno-organic compound and radical scavenger ebselen on rat hippocampal astrocytes in culture. Throughout our study we carried out determinations of [Ca2+](c) in fura-2-loaded cells by single cell imaging, glutamate secretion employing an enzymatic-based assay and GFAP expression, which was monitorized by immunocytochemistry and confocal microscopy. Our results show that ebselen (1-20microM) dose dependently increases [Ca2+](c), stimulates glutamate release and increases GFAP content, a hallmark of astrocyte reactivity. Ebselen did not alter significantly cell viability as assayed by determination of LDH release into the extracellular medium. Ebselen-evoked glutamate release and increase in GFAP content were Ca2+-dependent, because incubation of astrocytes in the absence of extracellular Ca2+ (medium containing 0.5mM EGTA) and in the presence of the intracellular Ca2+ chelator BAPTA (10microM) significantly reduced ebselen-evoked changes in these parameters. The effects of ebselen we have observed may underline various signalling pathways which are important for cell proliferation, differentiation and function. However, aberrations in astroglial physiology could significantly compromise brain function, due to their role as modulators of neuron activity. Therefore, we consider that careful attention should be paid when employing ebselen as a prophylactic agent against brain damage.


Assuntos
Astrócitos/metabolismo , Azóis/farmacologia , Cálcio/metabolismo , Citosol/metabolismo , Proteína Glial Fibrilar Ácida/metabolismo , Ácido Glutâmico/metabolismo , Hipocampo/citologia , Hipocampo/metabolismo , Fármacos Neuroprotetores/farmacologia , Compostos Organosselênicos/farmacologia , Animais , Animais Recém-Nascidos , Astrócitos/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Células Cultivadas , Citosol/efeitos dos fármacos , Retículo Endoplasmático/efeitos dos fármacos , Retículo Endoplasmático/metabolismo , Hipocampo/efeitos dos fármacos , Imuno-Histoquímica , Isoindóis , L-Lactato Desidrogenase/metabolismo , Ratos , Ratos Wistar
4.
Haematologica ; 89(9): 1142-4, 2004 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-15377479

RESUMO

We clearly show that plasma membrane Ca2+ ATPase (PMCA) activity is lower in platelets from patients with non-insulin-dependent diabetes mellitus (NIDDM) than in those from healthy controls. The lower activity is likely due to reduced PMCA expression and increased tyrosine phosphorylation. These findings provide an explanation for the cellular ionic defects occurring in insulin resistant conditions.


Assuntos
Plaquetas/enzimologia , ATPases Transportadoras de Cálcio/deficiência , Proteínas de Transporte de Cátions/deficiência , Diabetes Mellitus Tipo 2/sangue , Processamento de Proteína Pós-Traducional , Adulto , Plaquetas/efeitos dos fármacos , Cálcio/sangue , ATPases Transportadoras de Cálcio/sangue , ATPases Transportadoras de Cálcio/química , Proteínas de Transporte de Cátions/sangue , Proteínas de Transporte de Cátions/química , Diabetes Mellitus Tipo 2/enzimologia , Feminino , Humanos , Resistência à Insulina , Ionomicina/farmacologia , Masculino , Fosforilação , Fosfotirosina/análise , ATPases Transportadoras de Cálcio da Membrana Plasmática , Ativação Plaquetária , Tapsigargina/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA